Clinical Trials

The University of Washington’s Memory and Brain Wellness Center/Alzheimer’s Disease Research Center serves as a site for observational studies and trials of potential treatments, prevention strategies, and new diagnostic approaches for Alzheimer’s disease and related neurodegenerative conditions, such as frontotemporal degeneration and Lewy Body dementia/Parkinson’s disease dementia, open for enrollment at UW Medicine.

Please visit the Alzheimer’s Disease Research Center (ADRC) website for up-to-date information on our clinical trials and studies.

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer’s Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU001

• MONEAD (NIH, Tsai, site PI): Longitudinal multi-center study of mothers with epilepsy, mothers without epilepsy, and non-pregnant women with epilepsy exploring the relationship between anti-epileptic drug exposure and outcomes in mother and child. 

• SLATE (NCT02844465; NIH, Hakimian, site PI): Device trial evaluating the safety and efficacy of the Visualase MRI-guided laser ablation system for necrotization or coagulation of epileptogenic foci in patients with intractable mesial temporal lobe epilepsy.

• Xenon (NCT03796962; Tsai, site PI): Phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial with an optional open-label extension evaluating the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive treatment in adult patients aged 18 to 75 years diagnosed with focal epilepsy.

• “Neural Suppression Pilot Study” (ITHS, Tsai, PI): Prospective cohort study of spatial suppression in motion detection, comparing people with mesial temporal lobe epilepsy and neocortical temporal lobe epilepsy. 

• “Genetic and protein biomarkers of post-traumatic epilepsy to improve prediction of PTE: a prospective study in an enriched patient population” (CURE, Hakimian, site PI): Longitudinal multi-center study of patients who have experienced head injury, exploring potential genetic and protein biomarkers that may predict development of post-traumatic epilepsy.

• “Dissecting the Cognitive Roles of the Hippocampus” (NIH, Kim, Co-I): Longitudinal multi-center study of patients with temporal lobe epilepsy, exploring the short and long-term neurocognitive outcomes associated with epilepsy surgery.

• “Open-loop and closed-loop direct electrical stimulation of the cortex”: This study investigates electrophysiological correlates of human cognitive, perceptual, and emotional processes, by performing neurocognitive tasks (plus electrocortical simulation) with epilepsy patients undergoing grid/ strip or sEEG monitoring.

• “The role of Place and Grid Cells in human spatial navigation and memory” (Ojemann, PI): This study investigates electrophysiological correlates of human cognitive and perceptual processes, by performing neurocognitive tasks with epilepsy patients undergoing sEEG (plus microelectrode) monitoring.

• “Molecular Genetic Studies of Developmental Disorders”: Tissue-specimen collection study aiming to expand the scope of genomic studies and consolidate key genotype and phenotype data among people with epilepsy undergoing epilepsy resection surgery, by collecting and analyzing living neurosurgical tissue, scalp tissue, and saliva.

• “Cellular and Circuit Organization of Human Brain Project” (Lein, PI): Tissue-specimen collection study seeking to understand the unique structural and functional characteristics of the human neocortex (and/or other brain structures) through analysis of living neurosurgical tissue obtained as part of epilepsy resection surgery.

• “Electrocorticographic (ECoG) and Electroencephalographic (EEG) study of epilepsy patients with use of video” (Rao, PI): Retrospective chart review aiming to characterize brain activity during non-experimental events by analyzing signals obtained from EEG and ECoG.

• “Epilepsy and dendritic excitability” (NIH, Poolos, PI): This project will study the phosphorylation-dependent mechanisms underlying defective trafficking of hyperpolarization-activated, cyclic nucleotide-gated (HCN) ion channels during the development of epilepsy. It will also explore the alterations in HCN-mediated currents caused by human HCN1 channel mutations producing early childhood epileptic encephalopathy.

• “Big data approach to assessing comparative efficacy of antiepileptic drugs in refractory epilepsy.” (NIH, Poolos, PI): This project will perform a comparative efficacy analysis of commonly used antiepileptic drug regimens using proprietary seizure diary datasets from SeizureTracker.com and My Seizure Diary from the Epilepsy Foundation.

• “Managing Epilepsy Well 2.0 (MEW) Network” (CDC, Robert Fraser, PI; Poolos, contributor): This project enables self-management of epilepsy co-morbidities using structured telephone and in-person education in English and in Spanish.

• “Multimeric Peptide Copolymer Formulations for Targeted Drug Delivery to Treat Nervous System Disorders.” (NIH, Drew Sellers, PI; Poolos contributor): This project novel methods for delivery of therapeutic peptides to the CNS.

• “Using online seizure diaries to compare antiepileptic drug efficacy” (American Epilepsy Society, Alexander Arnold, PI; Poolos mentor): This fellowship award will enable additional analysis of online seizure diary data to find improved AED regimens in refractory epilepsy.

• “Sourcerer IC: A web-based integrative multimodal workflow for epilepsy surgical planning.” (NIH, Holmes, Co-I)

• Open-loop and closed-loop direct electrical stimulation of the cortex: Ojemann PI

• Enroll -HD: A Prospective Registry Study in a Global Huntington’s Disease Cohort
• HD-Charge: Indirect and Out-of-Pocket Costs of Huntington’s Disease in the United States
• HD-Clarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington’s Disease
• AMT-130: Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington Disease
• PROOF-HD: PRidopidine’s Outcome On Function in Huntington Disease.
• KINECT-HD: Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease

The Adult Hydrocephalus Clinical Research Network (AHCRN) is a network of hospitals that conduct clinical research on hydrocephalus to improve treatment for the adult forms of hydrocephalus, including transitional patients who were diagnosed as children, those who acquire hydrocephalus as adults, and patients with normal pressure hydrocephalus.

Please visit the AHCRN website for up-to-date information on our clinical trials and studies.

• BEAT-MS: Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis
• EVOLVE-MS-1: A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1
• TREAT-MS: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial
• NCT03737851: A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

• Demand-driven Management of Essential Tremor
• RESET-RA: Vagus Nerve Stimulation for Moderate-to-Severe Rheumatoid Arthritis
• Neural Correlates of Deep Brain Stimulation
• Neural Correlates of Cognition
• Neural Correlates of OCD
• Neural Correlates of Dystonia

• GBM Pembrolizumab HSPCC: Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
• NEO-100-01: Safety and Efficacy Study in Recurrent Grade IV Glioma
• GBM Agile: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
• BMX-HGG-001: Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
• MK-4830: Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors

• ARCADIA-CSI: Cognition and Silent Infarcts — ancillary study to ARCADIA. Looking at the effects of ASA vs Apixaban on occurrence of silent strokes and memory loss after stroke.
• ASPIRE: Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery — randomized, double-blinded, phase 3 clinical trial designed to test the efficacy and safety of apixaban, compared with aspirin, in patients with a recent intracerebral hemorrhage (ICH) and high-risk non-valvular atrial fibrillation (AF).
• SATURN: Statins Use in Intracerebral Hemorrhage Patients — multi-center, pragmatic, prospective, randomized, open-label, and blinded end-point assessment (PROBE) clinical trial to determine the effects of continuation vs. discontinuation of statins on the risk of ICH recurrence during 24 months of follow-up in patients presenting with a spontaneous lobar lCH while taking a statin drug.
• Neuro-AFib Retrospective Data Repository — The purpose of this research is to better understand stroke etiology, stroke outcomes, and to evaluate stroke risk reduction measures in non-valvular atrial fibrillation patients.
• Novartis CBAF312X2207: A phase II, patient- and investigator-blinded, randomized, placebo-controlled study to evaluate efficacy, safety and tolerability of BAF312 (siponimod) in patients with stroke due to intracerebral hemorrhage (ICH).